Serge Louis Boulet

This inventor holds 11 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2008-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Serge Louis Boulet. Retrieved from https://idiyas.com/inventor/serge-louis-boulet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 3)

% Patents Active = 54.5

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 7.4

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

11 out of 4,514

Eli Lilly and Company

patents

Years Active: 2008-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11731984 - KRas G12C inhibitors (2023-08-22),

2. 11649247 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-05-16),

3. 11629156 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-04-18),

4. 11001596 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2021-05-11),

5. 10696665 - Mutant IDH1 inhibitors (2020-06-30),

6. 10253041 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors (2019-04-09),

7. 7666871 - Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses (2010-02-23),

8. 7521462 - 4-Amino-piperidine derivatives as monoamine uptake inhibitors (2009-04-21),

9. 7417064 - 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake (2008-08-26),

10. 7410996 - 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake (2008-08-12),

11. 7410982 - Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors (2008-08-12),

Of course! Here is an article about inventor Serge Louis Boulet:

Title: Inventor Profile: Serge Louis Boulet

Introduction:

Serge Louis Boulet is a prolific inventor based in Fishers, IN (US) who has made significant contributions to the field of cancer treatment through his innovative patented compounds. With 11 patents to his name, Boulet's work has garnered attention in the pharmaceutical industry for its potential impact on cancer therapy.

Latest Patents:

Among his latest patents are "KRas G12C inhibitors" and "7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors". These compounds offer promising avenues for the treatment of cancer, particularly in targeting mutations in key cancer-related genes.

Career Highlights:

Serge Louis Boulet is currently employed at Eli Lilly and Company, a renowned pharmaceutical corporation. His association with this esteemed company underscores his expertise and dedication to advancing cancer research and drug development.

Collaborations:

Notable collaborators of Serge Louis Boulet include Renato Alejandro Bauer and Timothy Paul Burkholder. Together, they form a dynamic team at Eli Lilly and Company, working towards innovative solutions in oncology and beyond.

Conclusion:

In conclusion, Serge Louis Boulet's commitment to innovation in cancer treatment is evident through his numerous patents and collaborations in the pharmaceutical industry. His cutting-edge research continues to pave the way for advancements in cancer therapy, offering hope to patients worldwide.

Profile summary based on public USPTO records.